E. Johnson

发表

Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.

D. Denning, K. Oakley, S. Radford, 1997, The Journal of antimicrobial chemotherapy.

Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans.

E. Johnson, D. Warnock, K. Davey, 1998, The Journal of antimicrobial chemotherapy.

Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints

M. Ghannoum, J. Rex, T. Walsh, 2006, Journal of Clinical Microbiology.

Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990–9)

E. Johnson, T. Lamagni, B. G. Evans, 2001, Epidemiology and Infection.

Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods

M. Ghannoum, B. Alexander, J. Rex, 2009, Journal of Clinical Microbiology.

Management and outcome of bloodstream infections due to Candida species in England and Wales.

W. Gransden, C. Kibbler, J. Perry, 2003, The Journal of hospital infection.

Aspergillus antigen testing in bone marrow transplant recipients

Elizabeth M. Johnson, E. Johnson, D. Warnock, 2000, Journal of clinical pathology.

Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man.

E. Johnson, D. Warnock, M. Richardson, 1983, The Journal of antimicrobial chemotherapy.

In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.

E. Johnson, D. Warnock, A. Székely, 1998, The Journal of antimicrobial chemotherapy.

Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection—Scotland, 2012–2013

R. Rajendran, C. Munro, A. Sherriff, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata.

E. Johnson, D. Warnock, D. White, 1993, Genitourinary medicine.

Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis.

A. Wardley, B. Oppenheim, E. Johnson, 1996, The Journal of infection.

In-vitro resistance to imidazole antifungals in Candida albicans.

E. Johnson, D. Warnock, M. Richardson, 1984, The Journal of antimicrobial chemotherapy.

Rhizopus microsporus in wooden tongue depressors: a major threat or minor inconvenience?

C. K. Campbell, E. Johnson, D. Warnock, 1998, The Journal of hospital infection.

Fluconazole resistance in Candida glabrata

P. Troke, E. Johnson, D. Warnock, 1993, Antimicrobial Agents and Chemotherapy.

FLUCONAZOLE RESISTANCE IN CANDIDA GLABRATA

E. Johnson, D. Warnock, J. Burke, 1988, The Lancet.

Toxic gas generation from plastic mattresses and sudden infant death syndrome

C. K. Campbell, E. Johnson, D. Warnock, 1995, The Lancet.

Safety of Sanguinaria extract as used in commercial toothpaste and oral rinse products.

H. Maibach, D. Brusick, C. S. Weil, 1990, Journal.

Trends in laboratory‐diagnosed onychomycosis between 2006 and 2014 in the South West of England

A. Trickey, D. D. de Berker, E. Johnson, 2017, The British journal of dermatology.

Nail infection caused by Onychocola canadensis: report of the first four British cases.

C. K. Campbell, E. Johnson, D. Warnock, 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

MODIFIED RESPONSE TO KETOCONAZOLE OF CANDIDA ALBICANS FROM A TREATMENT FAILURE

E. Johnson, D. Warnock, M. Richardson, 1983, The Lancet.

Effect of imidazole antifungals on the development of germ tubes by strains of Candida albicans.

E. Johnson, D. Warnock, M. Richardson, 1983, The Journal of antimicrobial chemotherapy.

Influence of food on the pharmacokinetics of ketoconazole

E. Johnson, D. Warnock, M. Richardson, 1984, Antimicrobial Agents and Chemotherapy.

Effect of Ketoconazole on the Initial Stages of Germ Tube Formation by Strains of Candida albicans

E. Johnson, D. Warnock, M. L. Barnard, 1982, Mykosen.

In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes.

P. J. Elliot, E. Johnson, D. Warnock, 1992, The Journal of antimicrobial chemotherapy.

In-vitro effect of itraconazole, ketoconazole and amphotericin B on the phagocytic and candidacidal function of human neutrophils.

E. Johnson, D. Warnock, M. Richardson, 1986, The Journal of antimicrobial chemotherapy.

Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.

C Scully, C. Scully, Elizabeth M. Johnson, 1995, The Journal of antimicrobial chemotherapy.

Disseminated infection due to Cylindrocarpon lichenicola in a patient with acute myeloid leukaemia.

A. Mehta, C. Kibbler, E. Johnson, 1997, The Journal of infection.

Use of the Pastorex aspergillus antigen latex agglutination test for the diagnosis of invasive aspergillosis.

E. Johnson, D. Warnock, E. Evans, 1995, Journal of clinical pathology.

Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.

D. Denning, K. Oakley, P. Warn, 2000, The Journal of antimicrobial chemotherapy.

An outbreak of aspergillosis in a general ITU.

H Humphreys, H. Humphreys, S. Willatts, 1991, The Journal of hospital infection.

Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.

T. Rogers, E. Johnson, D. Warnock, 1998, The Journal of antimicrobial chemotherapy.

Candidosis of the genital tract in non-pregnant women.

P. Gough, E. Johnson, D. Warnock, 1985, European journal of obstetrics, gynecology, and reproductive biology.

Alternative approaches to the therapeutic drug monitoring of prophylactic posaconazole in haematology patients.

E. Yannaki, E. Johnson, D. Oliver, 2018, Journal de mycologie medicale.

Clinical manifestations and management of hyalohyphomycosis, phaeohyphomycosis and other uncommon forms of fungal infection in the compromised patient.

E. Johnson, D. Warnock, M. Richardson, 1990 .

Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods

J. Guarro, J. Turnidge, A. Chowdhary, 2017, Antimicrobial Agents and Chemotherapy.

In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens

S. Radford, E. Johnson, D. Warnock, 1997, Antimicrobial agents and chemotherapy.

Influence of formulation on ketoconazole pharmacokinetics in man: comparison of standard tablet versus capsule containing citric acid.

E. Johnson, D. Warnock, T. Daneshmend, 1986, The Journal of antimicrobial chemotherapy.

Posaconazole MIC Distributions for Aspergillus fumigatus Species Complex by Four Methods: Impact of cyp51A Mutations on Estimation of Epidemiological Cutoff Values

Pfaller, J. Guarro, J. Turnidge, 2018, Antimicrobial Agents and Chemotherapy.

In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole.

E. Johnson, D. Warnock, K. Davey, 1998, The Journal of antimicrobial chemotherapy.

Posaconazole MIC distributions for Aspergillus fumigatus SC by four methods: Impact of Cyp51A mutations on estimation of epidemiological cutoff values (ECVs/ECOFFs)

J. Guarro, J. Turnidge, A. Chowdhary, 2018 .

Disseminated Sporothix schenckii in a patient with AIDS.

D. Jenkins, I. Stephenson, M. Wiselka, 2005, The Journal of infection.

Isolation of the Fungus Geosmithia argillacea in Sputum of People with Cystic Fibrosis

J. Houbraken, R. Barton, R. Hobson, 2010, Journal of Clinical Microbiology.

Azole resistance in Candida albicans.

J. V. van Cutsem, E. Johnson, D. Warnock, 1986, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species.

E. Johnson, D. Warnock, K. Davey, 1995, The Journal of antimicrobial chemotherapy.

Aspergillus antigen latex test for diagnosis of invasive aspergillosis

E. Johnson, D. Warnock, J. Cornish, 1991, The Lancet.

Sporobolomyces roseus in the cerebrospinal fluid of an immunocompetent patient--to treat or not to treat?

E. Johnson, H. Humphreys, J. Moroney, 2012, Journal of medical microbiology.

Effect of methotrexate alone and in combination with antifungal drugs on the growth of Candida albicans.

E. Johnson, D. Warnock, J. Burke, 1989, The Journal of antimicrobial chemotherapy.

Complement Factor H in cSCC: Evidence of a Link Between Sun Exposure and Immunosuppression in Skin Cancer Progression

Elizabeth E. Hull, E. Johnson, Kathryn J. Leyva, 2022, Frontiers in Oncology.

Yeasticidal activity of chemical disinfectants and antiseptics against Candida auris.

A. Borman, C. Brown, Elizabeth M. Johnson, 2017, The Journal of hospital infection.